Pharmacological efforts to target specific RTKs, such as EGFR and MET; antiangiogenic therapies; and recent immunotherapy-based approaches have not yet demonstrated prominent therapeutic benefits for a large cohort of patients with GBM, emphasizing an urgent need for novel, effective anti-GBM therapeutic approaches (2). The gene discussed is MET; the disease is glioblastoma.